Patents by Inventor Caroline Elisabeth Rasmussen
Caroline Elisabeth Rasmussen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230103820Abstract: The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an EC50 that is at least 20-fold higher than the EC50 of the corresponding free CNP agonist and which released CNP agonist has an EC50 that is at most 3-fold higher than the EC50 of the corresponding free CNP agonist; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.Type: ApplicationFiled: June 13, 2022Publication date: April 6, 2023Inventors: Kennett SPROGØE, Harald Rau, Felix Cleemann, Ulrich Hersel, Caroline Elisabeth Rasmussen
-
Publication number: 20220409700Abstract: The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled-release CNP agonist and to methods of treatment.Type: ApplicationFiled: May 24, 2022Publication date: December 29, 2022Inventors: Kennett Sprogøe, Harald Rau, Felix Cleemann, Ulrich Hersel, Caroline Elisabeth Rasmussen
-
Publication number: 20220331438Abstract: The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with the CNP prodrugs of the present invention.Type: ApplicationFiled: June 16, 2022Publication date: October 20, 2022Inventors: Harald RAU, Ulrich HERSEL, Felix CLEEMANN, Caroline Elisabeth RASMUSSEN
-
Publication number: 20220296682Abstract: The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.Type: ApplicationFiled: November 15, 2021Publication date: September 22, 2022Applicant: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
-
Patent number: 11413351Abstract: The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with the CNP prodrugs of the present invention.Type: GrantFiled: January 5, 2017Date of Patent: August 16, 2022Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
-
Patent number: 11389510Abstract: The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an EC50 that is at least 20-fold higher than the EC50 of the corresponding free CNP agonist and which released CNP agonist has an EC50 that is at most 3-fold higher than the EC50 of the corresponding free CNP agonist; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.Type: GrantFiled: January 5, 2017Date of Patent: July 19, 2022Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Kennett Sprogøe, Harald Rau, Felix Cleemann, Ulrich Hersel, Caroline Elisabeth Rasmussen
-
Patent number: 11389511Abstract: The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled-release CNP agonist and to methods of treatment.Type: GrantFiled: January 5, 2017Date of Patent: July 19, 2022Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Kennett Sprogøe, Harald Rau, Felix Cleemann, Ulrich Hersel, Caroline Elisabeth Rasmussen
-
Patent number: 11154593Abstract: The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.Type: GrantFiled: February 24, 2021Date of Patent: October 26, 2021Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
-
Publication number: 20210177942Abstract: The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.Type: ApplicationFiled: February 24, 2021Publication date: June 17, 2021Applicant: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
-
Publication number: 20210077584Abstract: The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.Type: ApplicationFiled: August 27, 2020Publication date: March 18, 2021Inventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
-
Patent number: 10835578Abstract: The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.Type: GrantFiled: January 5, 2017Date of Patent: November 17, 2020Assignee: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
-
Publication number: 20190328840Abstract: The present invention relates to a controlled-release CNP agonist from which CNP agonist is released with a release half-life of at least 6 hours under physiological conditions and which controlled-release CNP agonist has an EC50 that is at least 20-fold higher than the EC50 of the corresponding free CNP agonist and which released CNP agonist has an EC50 that is at most 3-fold higher than the EC50 of the corresponding free CNP agonist; to pharmaceutical compositions comprising said controlled-release CNP agonist; their use; and to methods of treatment.Type: ApplicationFiled: January 5, 2017Publication date: October 31, 2019Inventors: Kennett SPROGØE, Harald Rau, Felix Cleemann, Ulrich Hersel, Caroline Elisabeth Rasmussen
-
Publication number: 20190328841Abstract: The present invention relates a pharmaceutical composition comprising a controlled-release CNP agonist which reduces CNP agonist-associated side-effects, the use of such controlled-release CNP agonist and to methods of treatment.Type: ApplicationFiled: January 5, 2017Publication date: October 31, 2019Inventors: Kennett Sprogøe, Harald Rau, Felix Cleemann, Ulrich Hersel, Caroline Elisabeth Rasmussen
-
Publication number: 20190015481Abstract: The present invention relates to a CNP prodrug or a pharmaceutically acceptable salt thereof comprising a CNP moiety -D; and a carrier moiety —Z that is conjugated through a moiety -L2- to a reversible prodrug linker moiety -L1-, which reversible prodrug linker moiety -L1- is covalently and reversibly conjugated to -D; wherein -L2- is a chemical bond or a spacer; and —Z is a polymer having a molecular weight of at least 10 kDa. It further relates to pharmaceutical compositions comprising the CNP prodrug or a pharmaceutically acceptable salt thereof, their use as a medicament and to methods of treatment.Type: ApplicationFiled: January 5, 2017Publication date: January 17, 2019Applicant: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen
-
Publication number: 20190008977Abstract: The present invention relates to CNP prodrugs in which the carrier is covalently and reversibly attached to the ring moiety of a CNP moiety, to pharmaceutical compositions comprising such CNP prodrugs, to their uses and to methods of treating diseases that can be treated with the CNP prodrugs of the present invention.Type: ApplicationFiled: January 5, 2017Publication date: January 10, 2019Applicant: ASCENDIS PHARMA GROWTH DISORDERS A/SInventors: Harald Rau, Ulrich Hersel, Felix Cleemann, Caroline Elisabeth Rasmussen